Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings has announced the appointment of Dr. Nermeen Varawalla as their new Chief Medical Officer, bringing over 25 years of extensive experience in the healthcare industry, including clinical trial services and medical affairs. Dr. Varawalla is expected to play a critical role in advancing Scancell’s cancer treatment trials, particularly as the company prepares for the Phase 2/3 registration study of their SCOPE-2 trial. Her appointment is viewed as a strategic enhancement to Scancell’s clinical team, promising to leverage her global expertise and successful track record in oncology drug development.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
